{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T20:48:45Z","timestamp":1779137325098,"version":"3.51.4"},"reference-count":55,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2019,1,19]],"date-time":"2019-01-19T00:00:00Z","timestamp":1547856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Charity : Gruppo Italiano Mesotelioma G.I.Me.","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Malignant mesothelioma (MMe) is a cancer with poor prognosis and resistance to standard treatments. Recent reports have highlighted the role of the BRCA1 associated protein 1 gene (BAP1) in the development of MMe. In this study, the chemosensitivity of human mesothelioma cell lines carrying BAP1 wild-type (WT), mutant and silenced was analysed. The BAP1 mutant cells were significantly less sensitive than BAP1 WT cell lines to the clinically relevant drug gemcitabine. Silencing of BAP1 significantly increased resistance of MMe cells to gemcitabine. Cell cycle analysis suggested that gemcitabine induced Sub-G1 phase accumulation of the BAP1 WT cells and increased in the S-phase in both BAP1 WT and mutant cells. Analysis of the role of BAP1 in apoptosis suggested that gemcitabine induced early apoptosis in both BAP1 WT and BAP1 mutant cells but with a much higher degree in the WT cells. Effects on the population of cells in late apoptosis, which can mark necrosis and necroptosis, could not be seen in the mutant cells, highlighting the possibility that BAP1 plays a role in several types of cell death. Significantly decreased DNA damage in the form of double-strand breaks was observed in gemcitabine-treated BAP1 mutant cells, compared to BAP1 WT cells under the same conditions. After BAP1 silencing, a significant decrease in DNA damage in the form of double-strand breaks was observed compared to cells transfected with scramble siRNA. Taken together, the results presented in this manuscript shed light on the role of BAP1 in the response of MMe cells to gemcitabine treatment and in particular in the control of the DNA damage response, therefore providing a potential route for more efficient MMe therapy.<\/jats:p>","DOI":"10.3390\/ijms20020429","type":"journal-article","created":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T03:08:22Z","timestamp":1548126502000},"page":"429","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["BAP1 Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment"],"prefix":"10.3390","volume":"20","author":[{"given":"Alice","family":"Guazzelli","sequence":"first","affiliation":[{"name":"School of Environment and Life Sciences, University of Salford, Salford M5 4WT, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parisa","family":"Meysami","sequence":"additional","affiliation":[{"name":"School of Environment and Life Sciences, University of Salford, Salford M5 4WT, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0091-1029","authenticated-orcid":false,"given":"Emyr","family":"Bakker","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Central Lancashire, Preston PR1 2HE, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4515-755X","authenticated-orcid":false,"given":"Constantinos","family":"Demonacos","sequence":"additional","affiliation":[{"name":"Faculty of Biology, Medicine and Health, School of Health Sciences, University of Manchester, Manchester M13 9PL, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Giordano","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Neuroscience, University of Siena, 53100 Siena, Italy"},{"name":"Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marija","family":"Krstic-Demonacos","sequence":"additional","affiliation":[{"name":"School of Environment and Life Sciences, University of Salford, Salford M5 4WT, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciano","family":"Mutti","sequence":"additional","affiliation":[{"name":"Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,1,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.rmed.2017.11.015","article-title":"Progress and challenges in Mesothelioma: From bench to bedside","volume":"134","author":"Blyth","year":"2018","journal-title":"Respir. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1080\/13543784.2017.1351545","article-title":"Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma","volume":"26","author":"Guazzelli","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1183\/09031936.00063109","article-title":"Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma","volume":"35","author":"Scherpereel","year":"2010","journal-title":"Eur. Respir. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.semdp.2006.08.002","article-title":"The pathogenesis of mesothelioma","volume":"23","author":"Carbone","year":"2006","journal-title":"Semin. Diagn. Pathol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/s41418-018-0213-5","article-title":"Consensus report of the 8 and 9th Weinman Symposia on Gene x Environment Interaction in carcinogenesis: Novel opportunities for precision medicine","volume":"25","author":"Carbone","year":"2018","journal-title":"Cell Death Differ"},{"key":"ref_6","first-page":"875","article-title":"Simian virus 40: The link with human malignant mesothelioma is well established","volume":"20","author":"Carbone","year":"2000","journal-title":"Anticancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1002\/(SICI)1097-0142(19990615)85:12<2577::AID-CNCR13>3.0.CO;2-S","article-title":"A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group","volume":"85","author":"Baas","year":"1999","journal-title":"Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0169-5002(00)00166-5","article-title":"Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B","volume":"31","author":"Kindler","year":"2001","journal-title":"Lung Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.lungcan.2014.03.006","article-title":"Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma","volume":"84","author":"Zauderer","year":"2014","journal-title":"Lung Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/annonc\/mdi187","article-title":"Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma","volume":"16","author":"Manegold","year":"2005","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/cncr.23337","article-title":"Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma","volume":"112","author":"Zucali","year":"2008","journal-title":"Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc3459","article-title":"BAP1 and cancer","volume":"13","author":"Carbone","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jtho.2016.04.028","article-title":"Consensus Report of the 2015 Weinman International Conference on Mesothelioma","volume":"11","author":"Carbone","year":"2016","journal-title":"J. Thoracic Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1073\/pnas.1309085110","article-title":"Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair","volume":"111","author":"Yu","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1128\/MCB.00847-15","article-title":"Role of Deubiquitinating Enzymes in DNA Repair","volume":"36","author":"Kee","year":"2016","journal-title":"Mol. Cell. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1038\/cdd.2017.95","article-title":"Germline BAP1 mutations induce a Warburg effect","volume":"24","author":"Bononi","year":"2017","journal-title":"Cell Death Differ."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1128\/MCB.00396-10","article-title":"The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and is a critical regulator of gene expression","volume":"30","author":"Yu","year":"2010","journal-title":"Mol. Cell. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"34179","DOI":"10.1074\/jbc.M109.046755","article-title":"The Deubiquitinating Enzyme BAP1 Regulates Cell Growth via Interaction with HCF-1","volume":"284","author":"Machida","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/ng.2323","article-title":"BAP1 loss defines a new class of renal cell carcinoma","volume":"44","author":"Liao","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/nsmb1332","article-title":"A YY1-INO80 complex regulates genomic stability through homologous recombination-based repair","volume":"14","author":"Wu","year":"2007","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"150018","DOI":"10.1098\/rsob.150018","article-title":"Ubiquitylation, neddylation and the DNA damage response","volume":"5","author":"Brown","year":"2015","journal-title":"Open Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3389\/fgene.2015.00282","article-title":"Fine-tuning the ubiquitin code at DNA double-strand breaks: Deubiquitinating enzymes at work","volume":"6","author":"Citterio","year":"2015","journal-title":"Front. Genet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e1969","DOI":"10.1038\/cddis.2015.305","article-title":"Oxidative phosphorylation-dependent regulation of cancer cell apoptosis in response to anticancer agents","volume":"6","author":"Yadav","year":"2015","journal-title":"Cell Death Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1016\/j.febslet.2013.10.035","article-title":"BAP1 is phosphorylated at serine 592 in S-phase following DNA damage","volume":"587","author":"Eletr","year":"2013","journal-title":"FEBS Lett."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jclinpath-2016-203866","article-title":"Gene of the month: BAP1","volume":"69","author":"Wang","year":"2016","journal-title":"J. Clin. Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/ng.910","article-title":"Germline mutations in BAP1 predispose to melanocytic tumors","volume":"43","author":"Wiesner","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1309\/AJCPG8LFJC0DHDQT","article-title":"Loss of BAP1 Expression in Basal Cell Carcinomas in Patients With Germline BAP1 Mutations","volume":"143","author":"Mochel","year":"2015","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.canlet.2015.09.011","article-title":"Germline BAP1 mutation in a family with high incidence of multiple primary cancers and a potential gene-environment interaction","volume":"369","author":"Cheung","year":"2015","journal-title":"Cancer Lett."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"270","DOI":"10.21037\/tlcr.2017.05.03","article-title":"BAP1, a tumor suppressor gene driving malignant mesothelioma","volume":"6","author":"Cheung","year":"2017","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"13432","DOI":"10.1073\/pnas.1612074113","article-title":"High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma","volume":"113","author":"Yoshikawa","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s10147-013-0619-5","article-title":"Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy","volume":"19","author":"Toyokawa","year":"2014","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ijc.1351","article-title":"Cell cycle effects of gemcitabine","volume":"93","author":"Cappella","year":"2001","journal-title":"Int. J. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"67754","DOI":"10.18632\/oncotarget.18834","article-title":"Cell cycle perturbation induced by gemcitabine in human tumor cells in cell culture, xenografts and bladder cancer patients: Implications for clinical trial designs combining gemcitabine with a Chk1 inhibitor","volume":"8","author":"Montano","year":"2017","journal-title":"Oncotarget"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/cas.12722","article-title":"Somatic alteration and depleted nuclear expression of BAP1 in human esophageal squamous cell carcinoma","volume":"106","author":"Mori","year":"2015","journal-title":"Cancer Sci."},{"key":"ref_39","first-page":"1065","article-title":"S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine","volume":"61","author":"Shi","year":"2001","journal-title":"Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12013-011-9184-6","article-title":"An emerging model for BAP1\u2032s role in regulating cell cycle progression","volume":"60","author":"Eletr","year":"2011","journal-title":"Cell Biochem. Biophys."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"8471","DOI":"10.1038\/ncomms9471","article-title":"BAP1 promotes breast cancer cell proliferation and metastasis by deubiquitinating KLF5","volume":"6","author":"Qin","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/jid.2014.528","article-title":"BAP1 has a survival role in cutaneous melanoma","volume":"135","author":"Kumar","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Matatall, K.A., Agapova, O.A., Onken, M.D., Worley, L.A., Bowcock, A.M., and Harbour, J.W. (2013). BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-371"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1158\/0008-5472.CAN-08-3355","article-title":"BRCA1-associated protein 1 interferes with BRCA1\/BARD1 RING heterodimer activity","volume":"69","author":"Nishikawa","year":"2009","journal-title":"Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1158\/0008-5472.CAN-14-0221","article-title":"Deubiquitination of \u03b3-Tubulin by BAP1 Prevents Chromosome Instability in Breast Cancer Cells","volume":"74","author":"Zarrizi","year":"2014","journal-title":"Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nature22798","article-title":"BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation","volume":"546","author":"Bononi","year":"2017","journal-title":"Nature"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"6953","DOI":"10.1158\/0008-5472.CAN-08-0365","article-title":"BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization","volume":"68","author":"Ventii","year":"2008","journal-title":"Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/cdd.2012.151","article-title":"Necrostatin-1 blocks both RIPK1 and IDO: Consequences for the study of cell death in experimental disease models","volume":"20","author":"Vandenabeele","year":"2013","journal-title":"Cell Death Differ."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1073\/pnas.1619588114","article-title":"BAP1 inhibits the ER stress gene regulatory network and modulates metabolic stress response","volume":"114","author":"Dai","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/s41419-018-1206-5","article-title":"BAP1 regulates different mechanisms of cell death","volume":"9","author":"Affar","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s41419-018-0500-6","article-title":"BAP1 induces cell death via interaction with 14-3-3 in neuroblastoma","volume":"9","author":"Sime","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12943-017-0587-x","article-title":"BAP1 dependent expression of long non-coding RNA NEAT-1 contributes to sensitivity to gemcitabine in cholangiocarcinoma","volume":"16","author":"Parasramka","year":"2017","journal-title":"Mol. Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1200\/JCO.2018.79.0352","article-title":"A Subset of Mesotheliomas With Improved Survival Occurring in Carriers of BAP1 and Other Germline Mutations","volume":"36","author":"Pastorino","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1158\/2159-8290.CD-17-0226","article-title":"DNA Damage and Repair Biomarkers of Immunotherapy Response","volume":"7","author":"Mouw","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/0003-4975(95)00045-M","article-title":"Characteristics of nine newly derived mesothelioma cell lines","volume":"59","author":"Pass","year":"1995","journal-title":"Ann. Thorac. Surg."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/2\/429\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:27:23Z","timestamp":1760185643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/2\/429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,19]]},"references-count":55,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,1]]}},"alternative-id":["ijms20020429"],"URL":"https:\/\/doi.org\/10.3390\/ijms20020429","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,19]]}}}